Primary membranous nephropathy (PMN) is an autoimmune disease that commonly presents as nephrotic syndrome. The treatment goal of patients with PMN is to induce remission. Current treatment options include the calcineurin inhibitors (cyclosporine and tacrolimus), cyclophosphamide, and rituximab.
This Health Technology Assessment examined the available evidence on the use of rituximab for PMN to determine its place in therapy relative to cyclophosphamide and the calcineurin inhibitors. An Implementation Advice Panel was convened to provide advice on initiation, discontinuation, and prescribing criteria for rituximab. These criteria reflect the panel members’ conclusions based on the best available evidence and their clinical expertise in the diagnosis and management of PMN. The advice will be used by the public drug plans to inform local decisions.